Skip to main content
. 2017 Apr 11;8(35):58480–58493. doi: 10.18632/oncotarget.17024

Figure 1. Osthole-mediated inhibition of breast cancer bone metastasis in mice.

Figure 1

(A) Radiograph images. (B) Whole-body bone scintigraphy images. (C) Pinhole bone scintigraphy images (arrows indicate sites of bone metastases). (D) Osthole diminished the incidence of bone metastasis (* p < 0.05 by the Fisher exact test). (E) Osthole reduced bone metastasis lesions (* p < 0.05 by ANOVA). (F) Representative images of osseous metastases. (G) Quantitative histomorphometry measurement of tumor burden in bone lesions (* p < 0.05 by ANOVA). Mice received an intracardiac injection of MDA-231BO cells, resulting in osseous metastases as detected by radionuclide bone scintigraphy and X-ray imaging within 2 weeks of tumor inoculation. The mice were then randomly divided into 2 groups (n=10 per group) that received either oral osthole (5.25 mg/kg) or vehicle twice weekly for 6 weeks. Every two weeks following inoculation, bone metastasis was evaluated by in vivo imaging with radiographs and radionuclide bone scintigraphy. Mice were sacrificed at the end of treatment, and metastatic bone lesions, observed by radionuclide scintigraphy and radiography, were sectioned and sent for H&E staining (magnification: 200X).